Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2022

09.12.2021 | original report

The outcome of COVID-19 in patients with hematological malignancy

verfasst von: Pınar Tığlıoğlu, Murat Albayrak, Mesut Tığlıoğlu, Hacer Berna Afacan Öztürk, Merih Reis Aras, Buğra Sağlam, Senem Maral

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Summary

Objective

The aim of this study was to examine the effect of coronavirus disease 2019 (COVID-19) on the malignancy-related clinical course and overall survival, and to determine the factors affecting mortality.

Methods

This retrospective study included 77 patients with hematological cancer and COVID-19. Patients were sub-grouped for analysis as survivors and non-survivors.

Results

COVID-19 was seen more frequently in myeloproliferative neoplasms (MPN), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) patients. Mortality rate due to COVID-19 was 20.8%. No statistically significant difference was determined between the survivor and non-survivor groups with respect to age and gender, presence of any comorbidity, leukocyte, neutrophil, lymphocyte, and monocyte values. Platelet count and hemoglobin count were significantly lower in the group with mortality than in the group with recovery.

Conclusion

It should be kept in mind that low hemoglobin and platelet levels contribute to mortality. In addition, it is important to protect patients with hematological cancer from COVID-19 and undertake effective vaccination due to its mortal course.
Literatur
1.
Zurück zum Zitat Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. CrossRefPubMedPubMedCentral Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55:5. Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55:5.
3.
Zurück zum Zitat Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049. CrossRef Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049. CrossRef
4.
Zurück zum Zitat Desai A, Sachdeva S, Parekh T, et al. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol. 2020;6:557–9. CrossRefPubMed Desai A, Sachdeva S, Parekh T, et al. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol. 2020;6:557–9. CrossRefPubMed
5.
Zurück zum Zitat Team CC‑R, Team CC‑R, Team CC‑R, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382–6. CrossRef Team CC‑R, Team CC‑R, Team CC‑R, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382–6. CrossRef
6.
Zurück zum Zitat Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10(7):935–41. CrossRefPubMedPubMedCentral Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10(7):935–41. CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e45. CrossRefPubMedPubMedCentral Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e45. CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–40. CrossRefPubMed Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–40. CrossRefPubMed
9.
Zurück zum Zitat Fontana L, Strasfeld L. Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient. Infect Dis Clin North Am. 2019;33(2):523–44. CrossRefPubMedPubMedCentral Fontana L, Strasfeld L. Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient. Infect Dis Clin North Am. 2019;33(2):523–44. CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Wood WA, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4(23):5966–75. CrossRefPubMedPubMedCentral Wood WA, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4(23):5966–75. CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York city. N Engl J Med. 2020;382(24):2372–4. CrossRefPubMed Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York city. N Engl J Med. 2020;382(24):2372–4. CrossRefPubMed
12.
Zurück zum Zitat Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. CrossRefPubMedPubMedCentral Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV‑2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382(22):2081–90. CrossRefPubMed Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV‑2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382(22):2081–90. CrossRefPubMed
14.
Zurück zum Zitat Sakurai A, Sasaki T, Kato S, et al. Natural history of asymptomatic SARS-CoV‑2 infection. N Engl J Med. 2020;383(9):885–6. CrossRefPubMed Sakurai A, Sasaki T, Kato S, et al. Natural history of asymptomatic SARS-CoV‑2 infection. N Engl J Med. 2020;383(9):885–6. CrossRefPubMed
15.
Zurück zum Zitat Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42. CrossRefPubMed Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42. CrossRefPubMed
16.
Zurück zum Zitat He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–45. CrossRefPubMed He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–45. CrossRefPubMed
17.
Zurück zum Zitat Martín-Moro F, Marquet J, Piris M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190(1):e16–e20. CrossRefPubMed Martín-Moro F, Marquet J, Piris M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190(1):e16–e20. CrossRefPubMed
19.
Zurück zum Zitat García-Suárez J, De La Cruz J, Cedillo Á, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):1–12. CrossRef García-Suárez J, De La Cruz J, Cedillo Á, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):1–12. CrossRef
20.
Zurück zum Zitat Cattaneo C, Daffini R, Pagani C, et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020;126(23):5069–76. CrossRefPubMed Cattaneo C, Daffini R, Pagani C, et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020;126(23):5069–76. CrossRefPubMed
21.
Zurück zum Zitat Kim JS, Lee KH, Kim G, et al. Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review. Eur Rev Med Pharmacol Sci. 2020;24(22):11926–33. PubMed Kim JS, Lee KH, Kim G, et al. Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review. Eur Rev Med Pharmacol Sci. 2020;24(22):11926–33. PubMed
22.
Zurück zum Zitat Shang W, Dong J, Ren Y, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020;92(10):2188–92. CrossRefPubMed Shang W, Dong J, Ren Y, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020;92(10):2188–92. CrossRefPubMed
23.
Zurück zum Zitat Lefrançais E, Ortiz-Muñoz G, Caudrillier A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544(7648):105–9. CrossRefPubMedPubMedCentral Lefrançais E, Ortiz-Muñoz G, Caudrillier A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544(7648):105–9. CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Yang X, Yang Q, Wang Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18(6):1469–72. CrossRefPubMed Yang X, Yang Q, Wang Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18(6):1469–72. CrossRefPubMed
25.
Zurück zum Zitat Yang M, Ng MH, Li CK. Thrombocytopenia in patients with severe acute respiratory syndrome (review). Hematology. 2005;10(2):101–5. CrossRefPubMed Yang M, Ng MH, Li CK. Thrombocytopenia in patients with severe acute respiratory syndrome (review). Hematology. 2005;10(2):101–5. CrossRefPubMed
26.
Zurück zum Zitat Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. CrossRefPubMed Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. CrossRefPubMed
27.
Zurück zum Zitat Anai M, Akaike K, Iwagoe H, et al. Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia. Respir Investig. 2021;59(2):187–93. CrossRefPubMed Anai M, Akaike K, Iwagoe H, et al. Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia. Respir Investig. 2021;59(2):187–93. CrossRefPubMed
28.
Zurück zum Zitat Doshi S, Rueda A, Corrales-Medina V, et al. Anemia and community-acquired pneumococcal pneumonia. Infection. 2011;39(4):379–83. CrossRefPubMed Doshi S, Rueda A, Corrales-Medina V, et al. Anemia and community-acquired pneumococcal pneumonia. Infection. 2011;39(4):379–83. CrossRefPubMed
29.
Zurück zum Zitat Reade MC, Weissfeld L, Angus DC, et al. The prevalence of anemia and its association with 90-day mortality in hospitalized community-acquired pneumonia. BMC Pulm Med. 2010;10(1):1–10. CrossRef Reade MC, Weissfeld L, Angus DC, et al. The prevalence of anemia and its association with 90-day mortality in hospitalized community-acquired pneumonia. BMC Pulm Med. 2010;10(1):1–10. CrossRef
Metadaten
Titel
The outcome of COVID-19 in patients with hematological malignancy
verfasst von
Pınar Tığlıoğlu
Murat Albayrak
Mesut Tığlıoğlu
Hacer Berna Afacan Öztürk
Merih Reis Aras
Buğra Sağlam
Senem Maral
Publikationsdatum
09.12.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00775-5

Weitere Artikel der Ausgabe 1/2022

memo - Magazine of European Medical Oncology 1/2022 Zur Ausgabe